In vivo Macroscopic Fluorescence Lifetime Molecular Optical Imaging

Information

  • Research Project
  • 10146317
  • ApplicationId
    10146317
  • Core Project Number
    R01CA250636
  • Full Project Number
    5R01CA250636-02
  • Serial Number
    250636
  • FOA Number
    PAR-19-158
  • Sub Project Id
  • Project Start Date
    5/1/2020 - 4 years ago
  • Project End Date
    4/30/2024 - 23 days ago
  • Program Officer Name
    SORG, BRIAN S
  • Budget Start Date
    5/1/2021 - 3 years ago
  • Budget End Date
    4/30/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/24/2021 - 2 years ago

In vivo Macroscopic Fluorescence Lifetime Molecular Optical Imaging

In vivo Macroscopic Fluorescence Lifetime Molecular Optical Imaging ABSTRACT There is still great need in better characterizing new targeted therapies in vivo, especially prior to clinical translation. In this regard, preclinical molecular imaging is a central tool in the targeted drug development pipeline. However, there is still a lack of integrated imaging platforms that can enable longitudinal (multiple time points) and spatially-resolved monitoring of complex fingerprints including molecular, metabolic and functional signatures in the same tumor/subject. This new integrated multiplexing imaging platform will play a crucial role in the development of the next generation of targeted drugs and elucidating (multi-) drug resistance mechanisms. Recently, we have demonstrated the unique capabilities of optical imaging in quantifying receptor-target engagement in live subjects by leveraging fluorescence lifetime. This outstanding achievement was realized thanks to the combination of instrumental, algorithmic and biochemical innovations to enable, for the first time, whole-body time-resolved optical imaging based on structured light for 2D or 3D Förster resonance energy transfer (FRET) imaging in live subjects. Herein, we will further impact the field of optical preclinical imaging and drug delivery assessment by 1) integrating a cutting-edge high-resolution, time-resolved SPAD array imager for improved photon collection efficiency, spatial resolution, and portability; 2) we will harness the latest developments in Deep Learning (DL) for ultra-fast, quantitative, but fitting/iterative inverse solver-free image formation, in both 2D and 3D providing image formation/processing solutions to facilitate multiplexed imaging; 3) we will implement new functionalities in our imaging platform to enable the concurrent longitudinal imaging of multiple clinically relevant target-receptor interactions (e.g. HER receptor family members involved in many cancers) as well as metabolic and functional status across the whole-tumor region in live intact animals.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    517757
  • Indirect Cost Amount
    116034
  • Total Cost
    633791
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
    NCI:633791\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    RENSSELAER POLYTECHNIC INSTITUTE
  • Organization Department
    BIOMEDICAL ENGINEERING
  • Organization DUNS
    002430742
  • Organization City
    TROY
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    121803590
  • Organization District
    UNITED STATES